UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State of incorporation or organization)	98-0376008 (I.R.S. Employer Identification No.)
Hi-Tech Park 2/5 Givat Ram PO Box 39098 Jerusalem, Israel (Address of principal executive offices)	<u>91390</u> (Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:	
Title of each class to be so registered	Name of each exchange on which each class is to be registered
Common stock, par value \$0.012 per share	The NASDAQ Stock Market LLC
f this form relates to the registration of a class of securities pursuant to Section 1 c), check the following box. \mathbf{x}	12(b) of the Exchange Act and is effective pursuant to General Instruction A.
f this form relates to the registration of a class of securities pursuant to Section 1 d), check the following box. o	12(g) of the Exchange Act and is effective pursuant to General Instruction A.
Securities Act registration statement file number to which this form relates:	<u>N/A</u> (if applicable)
Securities to be registered pursuant to Section 12(g) of the Act: None	
(Title of	class)

ITEM 1. Description of Registrant's Securities to be Registered.

The registrant's authorized capital stock consists of 16,666,667 shares of common stock, par value \$0.012 per share. Upon liquidation, dissolution or winding up of the registrant, the holders of common stock are entitled to share ratably in all net assets available for distribution to security holders after payment to creditors. The common stock is not convertible or redeemable and has no preemptive, subscription or conversion rights. Each outstanding share of common stock is entitled to one vote on all matters submitted to a vote of security holders. There are no cumulative voting rights. The holders of outstanding shares of common stock are entitled to receive dividends out of assets legally available therefore at such times and in such amounts as the registrant's board of directors may from time to time determine. Holders of common stock will share equally on a per share basis in any dividend declared by the registrant's board of directors. In the event of a merger or consolidation, all holders of common stock will be entitled to receive the same per share consideration.

ITEM 2. Exhibits.

Because no other securities of the registrant are registered on the NASDAQ Capital Market, and the securities being registered by this Registration Statement on Form 8-A are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended, no exhibits are required to be filed with this Registration Statement on Form 8-A.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

ORAMED PHARMACEUTICALS INC.

Dated: February 7, 2013

By: <u>/s/ Nadav Kidron</u> Nadav Kidron President and CEO